FRANKFURT, Aug 08 (AFP): American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 million plus royalties to settle US legal disputes over Covid-19 vaccines, CureVac said Friday.
The royalties would amount to a "single-digit" per centage on sales of Covid-19 vaccines in the United States, CureVac said.
The German firm added that it would grant Pfizer and BioNTech non-exclusive licence to make and sell mRNA-based Covid and flu products in the United States.
GSK, which since 2020 has worked with CureVac to develop mRNA vaccines for infectious diseases, said that it would receive $370 million as well as a one-per cent royalty on US sales of flu, Covid and "related combination mRNA vaccine products".
CureVac sued German rival BioNTech in 2022, arguing that BioNTech had infringed patents relating to mRNA technology in making its blockbuster Comirnaty coronavirus vaccine in colloboration with Pfizer.
Unlike traditional vaccines which contain some form of the dead or inactivated target virus,mRNA vaccines contain genetic materials that instruct human cells to make proteins typical of the targeted virus.
Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than conventional vaccines.
© 2025 - All Rights with The Financial Express
